EBUS-TBNA Diagnostic Procedure for Early-Stage Lung Cancer

Palo Alto (17 mi)

Overseen byGeorge Eapen, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial studies how well using ultrasound and a needle to take lung tissue samples after an imaging scan works in diagnosing early-stage lung cancer. It aims to improve the accuracy of determining the cancer stage in patients being considered for a specific type of radiation therapy.

Eligibility Criteria

This trial is for adults over 18 with early-stage non-small cell lung cancer (Stage I or IIa), who haven't had chemotherapy or radiotherapy for this cancer, and are being considered for a precise type of radiation therapy called SBRT. They must have had a PET/CT scan within the last 40 days and provided written consent. Cancer survivors can join if they've been free from active disease for at least five years.

Inclusion Criteria

My lung cancer is in the early stages (Stage I or IIa).

I am older than 18 years.

Exclusion Criteria

I am already scheduled for standard cancer treatments other than at disease progression.

My cancer is a type of well-differentiated neuroendocrine tumor.

I have had chemotherapy or radiotherapy for my cancer.

Treatment Details

The study is testing how well EBUS-TBNA works in diagnosing patients after they've had a PET/CT scan. It aims to improve accuracy in detecting early-stage lung cancer among those evaluated for stereotactic body radiation therapy.

1Treatment groups

Experimental Treatment

Group I: EBUS-TBNAExperimental Treatment1 Intervention

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT. A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope.